Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: A report from the French Society of Bone Marrow and Cellular Therapy

Haematologica

Volumn 98, Issue 5, 2013, Pages 776-783

  Coman, Tereza ^a   Bachy, Emmanuel ^b   Michallet, Mauricette ^b   Socié, Gérard ^c   Uzunov, Madalina ^d   Bourhis, Jean Henri ^e   Lapusan, Simona ^f   Brebion, Alain ^g   Vigouroux, Stéphane ^h   Maury, Sébastien ⁱ   François, Sylvie ^j   Huynh, Anne ^k   Lioure, Bruno ^l   Yakoub Agha, Ibrahim ^m   Hermine, Olivier ^a   Milpied, Noël ^h   Mohty, Mohamad ^f,n,o   Rubio, Marie Thérèse ^f,n,o  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g CHU Fort de France   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k CHU PURPAN   (France)

^l HÔPITAL DE HAUTEPIERRE   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HUMAN; IMMUNOMODULATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SALVAGE THERAPY; VENOUS THROMBOEMBOLISM; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84877050776     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.069328     Document Type: Article

References (23)

1. Gahrton G. Progress in allogeneic transplantation for multiple myeloma. Eur J Haematol. 2010;85(4):279-89.
2. Bensinger WI. The current status of reducedintensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia. 2006;20(10):1683-9.
3. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9): 3447-54.
4. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107(8):3415-6.
5. Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37(7):791-8.
6. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N, et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2005;35(2):165-9.
7. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-42.
8. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32.
9. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 (Suppl 1):S13-9.
10. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005; 128(2):192-203.
11. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia. 2009; 23(3):605-7.
12. El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C, et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol. 2012;40(7):521-7.
13. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413-9.
14. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-5.
15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
16. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica. 2006;91(6):837-9.
17. El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, et al. High response rate and improved graft-versus- host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93(3):455-8.
18. Mateos-Mazon J, Perez-Simon JA, Lopez O, Hernandez E, Etxebarria J, San Miguel JF. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica. 2007;92(9):1295-6.
19. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-95.
20. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117(18): 4696-700.
21. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide- associated thrombosis in myeloma. Leukemia. 2008;22(2):414-23.
22. Dimopoulos MA, Palumbo A, Attal M, Beksac M, Davies FE, Delforge M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011; 25(5):749-60.
23. Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk. 2010;10(2): 138-43.